May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Self–reported Patient Compliance within the European Glaucoma Prevention Study
Author Affiliations & Notes
  • A.I. Troost
    Ophthalmology,
    Johannes Gutenberg University, Mainz, Germany
  • R. Troost
    Coordination Center for Clinical Trials,
    Johannes Gutenberg University, Mainz, Germany
  • O.K. Schwenn
    Ophthalmology,
    Johannes Gutenberg University, Mainz, Germany
  • S. Kaiser
    Psychology,
    Johannes Gutenberg University, Mainz, Germany
  • U. Luka–Krausgrill
    Psychology,
    Johannes Gutenberg University, Mainz, Germany
  • N. Pfeiffer
    Ophthalmology,
    Johannes Gutenberg University, Mainz, Germany
  • EGPS–Group
    Johannes Gutenberg University, Mainz, Germany
  • Footnotes
    Commercial Relationships  A.I. Troost, None; R. Troost, None; O.K. Schwenn, None; S. Kaiser, None; U. Luka–Krausgrill, None; N. Pfeiffer, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4506. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.I. Troost, R. Troost, O.K. Schwenn, S. Kaiser, U. Luka–Krausgrill, N. Pfeiffer, EGPS–Group; Self–reported Patient Compliance within the European Glaucoma Prevention Study . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4506.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:The objective of this study was to assess self–reported compliance of patients within the European Glaucoma Prevention Study (EGPS) using an anonymous compliance questionnaire. Additionnaly we wanted to identify factors interfering with compliance. Methods:We developed an compliance questionnaire, which we validated and modified in a previous pilotstudy. It contains 59 questions with the following domains: demographic data, social background, medical history, information about disease, drop application habits, side effects, health behaviour / coping strategies. This questionnaire was handed out and collected anonymously to a subgroup of 370 study patients of the EGPS. Tests of statistical significance were conducted using regression analysis and Receiver Operating Curves (ROC). The effect of different variables was estimated controlling for the influence on compliance. Additionally for the variables with influence on compliance box plots were used to demonstrate the difference between compliant and noncompliant patients. Results:89% of patients returned the questionnaire. In total 67% of all patients reported not to miss eye drops more than once a week. There was no relevant difference between countries (Germany, Belgium, Portugal, Italy). In most cases (78%) the midday dose was missed. 56% of all patients reported side effects due to study medication. Side effect number one was "burning of the eyes", but 95% of all patients with side effects were not or only hardly disturbed in their everyday live. The only factor with reasonable ability to distinguish between compliant and noncompliant patients that might be used to predict whether a patient is compliant or not is "difficulties in applying eye drops". Conclusion:Compliance of the EGPS patients was very good. The main influencing factor was having difficulties in applying eye drops. Strategies to improve compliance could include giving proper instructions for eyedrop applications. Beside the clinical routine compliance data are critically important for a realistic interpretation of the results of clinical trials. To our knowledge this is the first report of self–reported compliance in a randomized, controlled, clinical, multicenter trial.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • clinical (human) or epidemiologic studies: health care delivery/economics/manpower • detection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×